EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’

EY Predicts Continued Emphasis On Bolt-On Deals, Partnerships In 2022

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.

Mergers
Expect another down year for major M&A, EY report predicts

Looking ahead, Ernst & Young expects the biopharmaceutical industry to continue the emphasis on partnerships and bolt-on acquisitions over company acquisitions seen in 2021, only perhaps at greater volume. The rationale for partnerships and bolt-ons simply is better than for large-scale M&A as biopharmas look to bolster their pipelines and portfolios against expected mid-decade patent cliff issues that are expected to drive down compound annual growth rates, the firm’s 2022 EY M&A Firepower Report asserts.

Released on the first day of the 2022 J.P. Morgan Healthcare Conference, this year’s report notes that life sciences merger...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.